|This article relies largely or entirely upon a single source. (July 2013)|
Magnesium salicylate is a common analgesic and non-steroidal anti-inflammatory drug (NSAID) used to treat mild to moderate muscular pain. It is also used to treat headaches, general back pain, and certain joint pains like arthritis.
It is found in a variety of over-the-counter (OTC) medications as an anti-inflammatory, primarily for back-pain relief. Magnesium salicylate can be an effective OTC alternative to prescription NSAIDs, with both anti-inflammatory and pain-relieving effects.
Though the recommended dosage is 1160 mg every six hours, per package directions of the Doan's OTC brand (580 mg magnesium salicylate tetrahydrate, equivalent to 467.2 mg anhydrous magnesium salicylate), effective pain relief is often found with a half dosage, with reduced anti-inflammatory results. note: Doan's extra strength OTC dose is 2 x 580 mg magnesium salicylate tetrahydrate every 6 hours, equivalent to 934.4 mg of anhydrous magnesium salicylate . magnesium salicylate is of the salicylate family and this compound is known to trigger Reye's Syndrome in children and adults, usually following a viral infection such as influenza or chicken pox. Products containing salicylates like magnesium salicylate should not be given to children under the age of 19.
While magnesium salicylate is an alternative for pain relief, it still is an NSAID like others in its category and can cause stomach ulcers, without any proven superiority over other over-the-counter type pain relievers (NSAID).
Doan's specifically, and the company producing it, Novartis, have been tried over their claim that the product is superior in providing pain relief. In June 1996, The FTC, Federal Trade Commission charged the company with violating federal law with its unsubstantiated claim. In March 1998, the court ruled in favor of the FTC but there was no stipulation about how the company should or would have to mend its advertising/packaging. Thus, Doan's was able to continue marketing as a "superior treatment for back pain".
In May of 1999 the FTC released a statement summarizing the proceedings and announced the commission's decision after a 4-0 vote imposing a penalty on Doan's and its marketer, Novartis, to "run ads to correct misbeliefs resulting from their unsubstantiated claim that Doan's Pills are superior to other over-the-counter analgesics for treating back pain" and to modify packaging to include the statement "Although Doan's is an effective pain reliever, there is no evidence that Doan's is more effective than other pain relievers for back pain." The ads were required to run for a period of one year.
- http://www.ftc.gov/opa/1999/05/doans.shtm Doan's Pills Must Run Corrective Advertising: FTC Ads Claiming Doan's Is Superior In Treating Back Pain Were Unsubstantiated
|This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it.|
|This analgesic-related article is a stub. You can help Wikipedia by expanding it.|